Truist Financial Corp. has announced a $10 billion share repurchase plan, up from its previous $5 billion, signaling a strong focus on enhancing shareholder value. Alongside this, Truist has adjusted its price targets for companies like Boston Scientific and NVIDIA Corporation to $130 and $275 per share, respectively, while maintaining Buy ratings across multiple stocks. The firm expresses optimism for the healthcare sector through 2026, despite facing challenges from its earlier merger of BB&T and SunTrust.
“Boston Scientific · was rated by · Truist · Buy”
“Truist · lifted its price target on · Boston Scientific · $130”
“Truist Securities · conducted · a survey · to gauge market sentiment”
“Truist · rated · NVIDIA Corporation · Buy”
“Truist · raised · price target for NVIDIA Corporation · $275 per share”
“Truist · lifted · its target for Cummins · to $522 from $434”
“Truist Securities · raised · the price target for FITB · $55”
“Truist · lowered the price target on Insulet · from $412 · to $390”
“Truist · maintains · a Buy rating · on the shares”
“Truist · expressed a positive outlook · on the healthcare sector · for 2026”
“Truist · lifted its price target to · $353 · high”
“Truist · reiterated · the stock · Buy”
